NorthWest Biotherapeutics Inc (NWBO)

[HyGro]

Regulatory approval is different than payer coverage. A drug or device must first be approved for commercial sale, then sponsor must get as many of the assorted payers to be willing to reimburse for the drug or device.

Optune's 35% newly diagnosed patient share are who GOT it - approved in the jurisdiction and reimbursed by a payer (or cash if the patient can afford it).

Many cancer treatments have very restrictive payer coverage. Yescarta, the leading CAR-T, another cell therapy, is approved in UK by MHRA, but NICE only will pay for 100 patients a year.